Natalizumab (Tysabri)

A humanized monoclonal immunoglobulin G4 antibody to human INTEGRIN ALPHA4 that binds to the alpha4 subunit of INTEGRIN ALPHA4BETA1 and integrin alpha4beta7. It is used as an IMMUNOLOGIC FACTOR in the treatment of RELAPSING-REMITTING MULTIPLE SCLEROSIS and CROHN'S DISEASE.

Also Known As:

Networked: 1808 relevant articles (233 outcomes, 305 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Gold, Ralf: 42 articles (01/2022 - 09/2007)
2.	Wiendl, Heinz: 35 articles (01/2022 - 06/2007)
3.	Killestein, Joep: 34 articles (01/2022 - 09/2010)
4.	Hartung, Hans-Peter: 33 articles (01/2021 - 04/2005)
5.	Kappos, Ludwig: 31 articles (01/2022 - 03/2006)
6.	Trojano, Maria: 30 articles (11/2022 - 12/2011)
7.	Wattjes, Mike P: 27 articles (05/2021 - 10/2013)
8.	Capra, Ruggero: 26 articles (01/2022 - 01/2012)
9.	Stüve, Olaf: 24 articles (01/2021 - 05/2006)
10.	Butzkueven, Helmut: 23 articles (02/2022 - 04/2014)

Related Diseases

1.	Multiple Sclerosis 10/01/2016 - "Clinical trials have shown that natalizumab is highly effective for treating relapsing forms of multiple sclerosis (MS). " 07/01/2011 - "Post hoc analysis of phase III clinical trials and the results of post-approval observational studies indicate that natalizumab significantly increases the proportion of patients with complete clinical and radiological response and is effective in patients with highly active forms of multiple sclerosis and suboptimal response to other treatments. " 05/01/2018 - "Natalizumab is highly effective in the treatment of relapsing multiple sclerosis patients. " 06/01/2014 - "MRI is the most powerful method in the detection of natalizumab-associated PML by showing imaging patterns helpful in the differentiation between PML and multiple sclerosis lesions. " 01/01/2013 - "Natalizumab inhibits the transmigration of activated T lymphocytes into the brain and is highly efficacious in multiple sclerosis (MS). "
2.	Relapsing-Remitting Multiple Sclerosis 07/01/2021 - "Natalizumab is a highly efficacious treatment for relapsing-remitting multiple sclerosis (RRMS). " 05/19/2014 - "Natalizumab is highly effective in relapsing-remitting multiple sclerosis and might be considered as an option. " 04/01/2014 - "Natalizumab is a highly effective treatment for patients with relapsing-remitting multiple sclerosis (RRMS). " 01/01/2013 - "Natalizumab is a highly effective treatment for relapsing-remitting multiple sclerosis (MS). " 01/01/2022 - "The high efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis (MS) is without controversy. "
3.	Progressive Multifocal Leukoencephalopathy 01/01/2023 - "Although highly efficacious, the immunosuppressive activity of natalizumab has been associated with JC polyomavirus-driven progressive multifocal leukoencephalopathy (PML). " 04/01/2011 - "Natalizumab was shown to be highly efficacious in the treatment of MS. However, the risk of progressive multifocal leukoencephalopathy was confirmed and defined better. " 03/21/2017 - "Progressive multifocal leukoencephalopathy (PML) associated with natalizumab treatment continues to be a severe problem of clinically successful therapy. " 01/01/2012 - "While having shown high therapeutic efficacy, treatment by natalizumab has been linked to progressive multifocal leukoencephalopathy (PML) as a serious adverse effect. " 01/01/2016 - "Natalizumab therapeutic efficacy is limited by the reactivation of the John Cunningham polyomavirus (JCV) and development of progressive multifocal leukoencephalopathy (PML). "
4.	Crohn Disease (Crohn's Disease) 01/01/2009 - "Natalizumab is already approved for clinical use and targets alpha4 with proven efficacy in Crohn's disease. " 01/02/2003 - "Natalizumab also produced a significant improvement in response rates (defined by a reduction of at least 70 points in the score on the Crohn's Disease Activity Index). " 01/02/2003 - "The group given two infusions of 6 mg of natalizumab per kilogram did not have a significantly higher rate of clinical remission (defined by a score of less than 150 on the Crohn's Disease Activity Index) than the placebo group at week 6 (the prospectively defined primary end point in the efficacy analysis). " 01/24/2007 - "Pooled data from the four included studies suggest that natalizumab (300 mg or 3 to 4 mg/kg) is effective for induction of clinical response and remission in patients with moderately to severely active Crohn's disease. " 07/19/2006 - "Pooled data and the results of an ongoing study suggest that natalizumab may be effective for induction of clinical response and remission in patients with moderately to severely active Crohn's disease. "
5.	Fatigue 11/15/2017 - "Natalizumab improved HRQoL quickly and sustainably in patients with relapsing-remitting MS. In terms of HRQoL, natalizumab seems to benefit mostly patients with more marked fatigue at baseline." 01/01/2013 - "Thus significant improvements in fatigue were maintained over time, and cognitive performance improved or remained stable up to 48 weeks after initiation of natalizumab in MS patients with some degree of fatigue. " 11/14/2023 - "Seven days after the natalizumab infusion, the 67 pwMS from the prospective cohort reported improvement in PRO measures of fatigue (62.8 vs. 66.4, p = 0.019), bladder limitations (80.3 vs. 85.0, p = 0.012), and feelings of lonesomeness (81.2 vs. 88.0, p = 0.009). " 01/01/2015 - "After 1 year of natalizumab treatment, the majority of patients (>92%) remained stable or improved in total, motor, and cognitive fatigue. " 01/01/2015 - "In the single-arm, observational phase IV TYNERGY study, relapsing-remitting MS patients showed a clinically meaningful decrease in fatigue over 1 year of treatment with natalizumab. "

Related Drugs and Biologics

1.	Monoclonal Antibodies
2.	Integrins
3.	Fingolimod Hydrochloride (FTY720)
4.	Natalizumab (Tysabri)
5.	nitazoxanide (NTZ)
6.	Interferon beta-1a
7.	Alemtuzumab (Campath)
8.	Antibodies
9.	Interferon-beta
10.	Integrin alpha4

Related Therapies and Procedures

1.	Therapeutics
2.	Injections
3.	Aftercare (After-Treatment)
4.	Hematopoietic Stem Cell Transplantation
5.	Art Therapy